News

Objective Capital Partners Adds CardioCell to Expanding Portfolio of Life Science Companies

Following Positive Results in Phase IIa Heart Failure Clinical Trial,

CardioCell Chooses Objective Capital to Help Manage Rapid Growth

SAN DIEGO – Sept. 7, 2016 – Objective Capital Partners, a leading middle market investment bank and mergers and acquisition (M&A) advisory firm focused on transactions for companies with enterprise values up to $500 million, is pleased to announce that it has recently been retained by CardioCell LLC to help manage its growth needs. CardioCell, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, recently announced positive data from its Phase IIa clinical trial “Safety and Efficacy of Intravenous Infusion of Ischemia-Tolerant Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Cardiomyopathy” at the European Society of Cardiology (ESC) Congress and is currently planning a Phase III study in early 2017. (more…)

Regen BioPharma, Inc. Retains Objective Capital Partners, LLC To Explore Non-Dilutive Funding Opportunities

San Diego, CA – June 7, 2016- Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), announced today that it has retained Objective Capital Partners, LLC as its advisor to assist the company in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide a source of non-dilutive funding.  The strategies being explored include partnering assets of the Company with the goal to provide a source of non-dilutive funding to primarily support Regen’s NR2F6, tCellVax and small molecule programs. (more…)

Objective Capital Partners Advises Marina Biotech on Creating Greater Shareholder Value with the Addition of a Late Stage Clinical Asset

San Diego, CA and Bothell, WA – May 17, 2016 –  Marina Biotech, Inc. (OTCQB:MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases, announced that the companies have executed a term sheet under which Marina intends to acquire Turing’s intranasal ketamine program. Pending the negotiation of the definitive agreement, Marina is expected to acquire Turing’s intranasal ketamine program for approximately 53 million Marina common shares. Objective Capital Partners, LLC served as an advisor to Marina Biotech in the transaction. (more…)

Objective Capital Partners Closes Deal Capitalization on Tavern+Bowl

San Diego, CA- May 10, 2016 – Objective Capital Partners, a leading middle market investment bank focused on transactions for companies with enterprise values up to $500 million, is pleased to announce the equity and debt capitalization of Tavern & Bowl, LLC. (Tavern+Bowl), a leading restaurant and hospitality group. Objective Capital Partners served as the lead financial advisor to Tavern+Bowl providing financial leadership from strategic options assessment, through redesigning the capital structure, financial modeling and supporting the capital acquisition. (more…)

Objective Capital Partners Retained by Marina Biotech to Explore Strategic Alternatives

Bothell, WA – February 18, 2016 – Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that its Board of Directors has authorized a process to explore a range of strategic alternatives to enhance shareholder value. The Company has retained Objective Capital Partners, LLC as its exclusive advisor to assist the company in exploring such alternatives. These alternatives will focus on building upon the Company’s strong foundation and could include selling, partnering or raising capital to continue growth and development in the business. (more…)

Objective Capital Partners Retained by AVACEN Medical Inc. to Explore Strategic Alternatives

San Diego, CA – February 2, 2016 – AVACEN Medical, a privately held medical device company, announced that its Board of Directors has authorized a process to explore a range of strategic alternatives to enhance shareholder value. The Company has retained Objective Capital Partners, LLC as its exclusive advisor to assist the company in exploring such alternatives. These alternatives, all of which are focused on building upon the Company’s strong foundation, could include selling, partnering or raising capital to continue growth and development in the business. (more…)